ticlopidine and ST Elevated Myocardial Infarction studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Research Excerpts

Excerpt	Relevance	Reference
"In smokers, a double-dose clopidogrel regimen reduced major cardiovascular events and stent thrombosis after percutaneous coronary intervention, with no increase in major bleeding."	9.24	Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. ( Bossard, M; Faxon, DP; Fox, KAA; Gao, P; Granger, CB; Jolly, SS; Mehta, SR; Montalescot, G; Natarajan, MK; Niemela, K; Steg, PG; Tanguay, JF; Widimsky, P; Yusuf, S, 2017)
"Bleeding is one of the possible adverse events during clopidogrel therapy."	7.88	Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel. ( Antonijevic, N; Kusic-Tisma, J; Matic, D; Novkovic, M; Radojkovic, D; Rakicevic, L, 2018)
"European guidelines recommend the use of ticagrelor versus clopidogrel in patients with ST elevation myocardial infarction (STEMI)."	7.85	Ticagrelor versus clopidogrel in real-world patients with ST elevation myocardial infarction: 1-year results by propensity score analysis. ( Boasi, V; Cattunar, S; Mascelli, G; Perri, D; Pistis, G; Sànchez, FA; Secco, GG; Tacchi, C; Vercellino, M, 2017)
"To evaluate the effect of bleedings for up to 12months on clinical events and therapeutic compliance in unselected STEMI patients treated with prasugrel or clopidogrel."	7.83	One-year incidence and clinical impact of bleeding events in patients treated with prasugrel or clopidogrel after ST-segment elevation myocardial infarction. ( Benezet, JF; Cayla, G; Cornillet, L; de La Coussaye, JE; Fabbro-Peray, P; Lattuca, B; Leclercq, F; Ledermann, B; Macia, JC; Messner-Pellenc, P; Schmutz, L, 2016)
"Clopidogrel as a potent antiplatelet agent is administered in patients with ST elevation myocardial infarction (STEMI)."	7.83	Clopidogrel loading dose in the management of ST elevation myocardial infarction: Still a debate! ( Alyasin, N, 2016)
" Newer P2Y12 antagonists with faster onset and greater inhibition of platelet activity have improved cardiovascular outcomes but have created uncertainty with the appropriate dosing when switching between agents."	5.46	In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention. ( Brice, AE; Haynick, M; Hernandez, GA; Mendoza, CE; Sanchez, M, 2017)
"HPR-aspirin was persistent 75days later in 36% patients."	5.43	High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction. ( Dillinger, JG; Drouet, L; Henry, P; Saeed, A; Sideris, G; Silberman, SM; Sollier, CB; Spagnoli, V; Voicu, S, 2016)
" Ticagrelor was more effective than clopidogrel in TAPT; however, when using the combination of aspirin, ticagrelor, and tirofiban, close monitoring is required for possible bleeding complications."	5.24	Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study. ( Chen, Q; Geng, G; Han, W; Hao, Y; Hao, Z; Jia, K; Liu, H; Liu, L; Liu, Y; Wang, D; Zhou, Y, 2017)
"In smokers, a double-dose clopidogrel regimen reduced major cardiovascular events and stent thrombosis after percutaneous coronary intervention, with no increase in major bleeding."	5.24	Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. ( Bossard, M; Faxon, DP; Fox, KAA; Gao, P; Granger, CB; Jolly, SS; Mehta, SR; Montalescot, G; Natarajan, MK; Niemela, K; Steg, PG; Tanguay, JF; Widimsky, P; Yusuf, S, 2017)
"Among patients with STEMI undergoing PPCI, ticagrelor reduces the incidence of MACCE and the composite end point of cardiovascular death, nonfatal MI, and stroke compared with clopidogrel."	5.22	Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. ( Jing, Q; Li, R; Liu, P; Liu, Y; Tang, X; Wang, Q; Zhang, P, 2016)
"Current clinical guidelines of acute coronary syndromes (ACS) recommend the use of potent antiplatelet therapy, prasugrel or ticagrelor, because both drugs consistently reduce cardiovascular events."	3.88	Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes. ( Candela Sánchez, E; Carrillo Alemán, L; Esteve-Pastor, MA; Lozano, T; MacíasVillanego, MJ; Marín, F; Orenes-Piñero, E; PerniasEscrig, V; Quintana-Giner, M; Rivera-Caravaca, JM; Ruíz-Nodar, JM; Sandín Rollán, M; Tello-Montoliu, A; Valdés, M; Véliz-Martínez, A; Vicente-Ibarra, N, 2018)
"Bleeding is one of the possible adverse events during clopidogrel therapy."	3.88	Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel. ( Antonijevic, N; Kusic-Tisma, J; Matic, D; Novkovic, M; Radojkovic, D; Rakicevic, L, 2018)
"Among 1469 patients with incident ST-elevation myocardial infarction (STEMI, 14%) or non-STEMI (86%), 390 patients were prescribed DAPT, 549 aspirin only, and 530 clopidogrel only."	3.88	Single and dual antiplatelet therapy in elderly patients of medically managed myocardial infarction. ( Chan, KA; Lai, CL; Lai, HY; Lai, MS; Lin, TT; Yang, YY, 2018)
"European guidelines recommend the use of ticagrelor versus clopidogrel in patients with ST elevation myocardial infarction (STEMI)."	3.85	Ticagrelor versus clopidogrel in real-world patients with ST elevation myocardial infarction: 1-year results by propensity score analysis. ( Boasi, V; Cattunar, S; Mascelli, G; Perri, D; Pistis, G; Sànchez, FA; Secco, GG; Tacchi, C; Vercellino, M, 2017)
"Prasugrel has proved its superiority over clopidogrel for reducing ischemic events among patients with ST elevation myocardial infarction (STEMI) undergoing urgent percutaneous coronary intervention (PCI)."	3.83	In-hospital switching from clopidogrel to prasugrel following thrombolysis for ST-elevation myocardial infarction: a 3-year single center experience. ( Arad, J; Gilutz, H; Lerman, TT; Reitblat, O; Shimony, A; Zahger, D, 2016)
"To evaluate the effect of bleedings for up to 12months on clinical events and therapeutic compliance in unselected STEMI patients treated with prasugrel or clopidogrel."	3.83	One-year incidence and clinical impact of bleeding events in patients treated with prasugrel or clopidogrel after ST-segment elevation myocardial infarction. ( Benezet, JF; Cayla, G; Cornillet, L; de La Coussaye, JE; Fabbro-Peray, P; Lattuca, B; Leclercq, F; Ledermann, B; Macia, JC; Messner-Pellenc, P; Schmutz, L, 2016)
"Clopidogrel as a potent antiplatelet agent is administered in patients with ST elevation myocardial infarction (STEMI)."	3.83	Clopidogrel loading dose in the management of ST elevation myocardial infarction: Still a debate! ( Alyasin, N, 2016)
"The long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in patients undergoing early percutaneous coronary intervention (PCI) after fibrinolytic therapy is unknown."	2.87	Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI. ( Bagai, A; Booker, J; Cantor, WJ; Cheema, AN; Crawford, JJ; Dehghani, P; Goodman, SG; Harenberg, S; Kelly, S; Lavi, S; Lavoie, A; Mehta, SR; Pon, Q; Yang, A; Zimmermann, RH, 2018)
"Fibrinolysis-treated STEMI patients who received clopidogrel and aspirin at the time of fibrinolysis and were undergoing early PCI frequently had PRU >208."	2.84	Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI. ( Bagai, A; Booker, J; Cantor, WJ; Cheema, AN; Crawford, JJ; Dehghani, P; Goodman, SG; Harenberg, S; Kelly, S; Lavi, S; Lavoie, A; Mehta, SR; Zimmermann, RH, 2017)
"Among 3,602 patients with STEMI who were enrolled in the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial, all ischemic and bleeding events, including recurrent events, were classified according to the timing of their occurrence as acute (≤24 h after PCI), subacute (1 day to 30 days), and late (30 days to 1 year)."	2.84	Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI. ( Brener, SJ; Dangas, GD; Deliargyris, EN; Généreux, P; Giustino, G; Kirtane, AJ; Mehran, R; Pocock, SJ; Prats, J; Redfors, B; Stone, GW, 2017)
"A total of 132 patients with STEMI within the first 12 hr of chest pain referred to primary angioplasty were randomized to upstream clopidogrel (600 mg), prasugrel (60 mg), or ticagrelor (180 mg) while still in the emergency room."	2.82	Upstream clopidogrel, prasugrel, or ticagrelor for patients treated with primary angioplasty: Results of an angiographic randomized pilot study. ( Croce, KJ; Falcão, FC; Falcão, JL; Lemos, PA; Medeiros, F; Mont'Alverne-Filho, JR; Nicolau, JC; Rodrigues-Sobrinho, CR; Serruys, PW; Silva, RC; Valgimigli, M, 2016)
"Residual intra-stent thrombus was quantified by optical coherence tomography using both the number of cross-sections with thrombus area more than 10% and thrombus volume."	2.82	Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction. ( Cattabiani, MA; Di Vito, L; Gatto, L; Limbruno, U; Marco, V; Micari, A; Pawlowski, T; Prati, F; Romagnoli, E; Trivisonno, A; Versaci, F, 2016)
"Ticagrelor has shown greater, more rapid and more consistent platelet inhibition than clopidogrel."	2.82	Randomised trial to compare a protective effect of Clopidogrel Versus TIcagrelor on coronary Microvascular injury in ST-segment Elevation myocardial infarction (CV-TIME trial). ( Baek, YS; Kim, DH; Kwan, J; Kwon, SW; Lee, MJ; Park, KS; Park, SD; Shin, SH; Woo, SI, 2016)
"In Japanese patients with STEMI who undergo primary PCI, prasugrel provides stronger platelet inhibition than clopidogrel from 3 h after loading, whereas platelet reactivity remained elevated within 24 h after clopidogrel loading."	2.82	Pharmacodynamic Assessment of Platelet Reactivity After a Loading Dose of Prasugrel or Clopidogrel in Patients With ST-Segment Elevation Myocardial Infarction. ( Ebina, T; Hibi, K; Ichikawa, S; Iwahashi, N; Kimura, K; Kimura, Y; Kosuge, M; Maejima, N; Matsuzawa, Y; Minamimoto, Y; Tsukahara, K, 2016)
"Clinical trials enrolling STEMI patients were identified and relevant data was extracted."	2.53	Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis. ( Baber, U; Berger, PB; Currier, J; Dave, RH; Henry, TD; Mehran, R; Nayyar, P; Rafique, AM; Tobis, J; Wang, TY, 2016)
"ST-elevation myocardial infarction (STEMI), which constitutes nearly 25-40 % of current acute myocardial infarction (AMI) cases, is a medical emergency that requires prompt recognition and treatment."	2.53	Contemporary management of ST-segment elevation myocardial infarction. ( Flaherty, JD; Gajjar, M; Ricciardi, MJ; Schimmel, DR; Yadlapati, A, 2016)
"Setting Department for the Treatment of Acute Coronary Syndrome in tertiary teaching hospital, Serbia."	1.48	The association of clopidogrel and 2-oxo-clopidogrel plasma levels and the 40 months clinical outcome after primary PCI. ( Apostolovic, S; Konstantinovic, SS; Lilic, J; Marinkovic, V; Nikolic, VN; Pavlovic, M; Stokanovic, D; Zvezdanovic, JB, 2018)
"Patients with STEMI undergoing PPCI within 12hours of symptoms onset were included prospectively."	1.46	Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. ( Aitmokhtar, O; Azaza, A; Azzouz, A; Benamara, S; Benathmane, T; Benkhedda, S; Bonello, L; Bouzid, A; Hamza, O; Harbi, F; Kara, M; Monsuez, JJ; Paganelli, F; Saidane, M; Seddiki, S; Sik, A, 2017)
"Hemorrhagic stroke is not the only complication of thrombolysis, ischemic stroke can occur even if it is an extremely rare complication."	1.46	Ischemic stroke complicating thrombolytic therapy with tenecteplase for ST elevation myocardial infarction: two case reports. ( Arous, S; Bentaoune, T; El Ghali Benouna, M; Habbal, R; Haboub, M, 2017)
" Newer P2Y12 antagonists with faster onset and greater inhibition of platelet activity have improved cardiovascular outcomes but have created uncertainty with the appropriate dosing when switching between agents."	1.46	In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention. ( Brice, AE; Haynick, M; Hernandez, GA; Mendoza, CE; Sanchez, M, 2017)
"Seven-hundred and thirteen consecutive STEMI patients undergoing PPCI, admitted to the S."	1.46	Prognostic Factors in Patients With Stemi Undergoing Primary PCI in the Clopidogrel Era: Role of Dual Antiplatelet Therapy at Admission and the Smoking Paradox on Long-Term Outcome. ( Barbato, E; Bartunek, J; Ciccarelli, G; Cimmino, G; De Bruyne, B; Di Girolamo, D; Di Serafino, L; Golino, M; Golino, P; Wijns, W, 2017)
" The time interval from ADP receptor blocker loading dosing to the blood sampling was similar in T2D and ND patients in both examinations."	1.43	The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study. ( Bolek, T; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Stančiaková, L; Staško, J, 2016)
"HPR-aspirin was persistent 75days later in 36% patients."	1.43	High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction. ( Dillinger, JG; Drouet, L; Henry, P; Saeed, A; Sideris, G; Silberman, SM; Sollier, CB; Spagnoli, V; Voicu, S, 2016)
"All hematomas were without clinical consequences."	1.43	Access-site bleeding and radial artery occlusion in transradial primary percutaneous coronary intervention: influence of adjunctive antiplatelet therapy. ( Bernat, I; Dragounová, E; Hromádka, M; Jirouš, Š; Pechman, V; Rokyta, R; Seidlerová, J; Tůmová, P, 2016)

Research

Studies (56)

Authors

Clinical Trials (7)

Trial Overview

Trial Outcomes

Number of Patients With All Cause Death and Non-fatal Stroke

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	54 (96.43)	24.3611
2020's	2 (3.57)	2.80

Authors	Studies
Yao, Y	1
Li, X	2
Wang, Z	1
Xu, S	1
Lv, Q	1
Landi, A	1
De Servi, S	2
Vercellino, M	1
Sànchez, FA	1
Boasi, V	1
Perri, D	1
Tacchi, C	1
Secco, GG	1
Cattunar, S	1
Pistis, G	1
Mascelli, G	1
Jang, HJ	1
Park, SD	2
Park, HW	2
Suh, J	1
Oh, PC	1
Moon, J	1
Lee, K	1
Kang, WC	1
Kwon, SW	2
Kim, TH	1
Shavadia, J	1
Welsh, R	1
Gershlick, A	1
Zheng, Y	1
Huber, K	1
Halvorsen, S	1
Steg, PG	2
Van de Werf, F	1
Armstrong, PW	1
Aitmokhtar, O	1
Paganelli, F	1
Benamara, S	1
Azaza, A	1
Bonello, L	1
Hamza, O	1
Seddiki, S	1
Benathmane, T	1
Saidane, M	1
Bouzid, A	1
Kara, M	1
Sik, A	1
Azzouz, A	1
Harbi, F	1
Monsuez, JJ	1
Benkhedda, S	1
Arous, S	1
Haboub, M	1
El Ghali Benouna, M	1
Bentaoune, T	1
Habbal, R	1
Liu, Y	2
Liu, H	1
Hao, Y	1
Hao, Z	1
Geng, G	1
Han, W	1
Chen, Q	1
Wang, D	1
Liu, L	1
Jia, K	1
Zhou, Y	1
Shiran, A	1
Adawi, S	1
Rubinshtein, R	1
Bardicef, M	1
Gutterman, E	1
Erathi, HV	1
Durgaprasad, R	1
Velam, V	1
Pvgk, S	1
Rodda, M	1
C, K	1
Kanavath, SN	1
Esteve-Pastor, MA	1
Ruíz-Nodar, JM	1
Orenes-Piñero, E	1
Rivera-Caravaca, JM	1
Quintana-Giner, M	1
Véliz-Martínez, A	1
Tello-Montoliu, A	1
PerniasEscrig, V	1
Sandín Rollán, M	1
Vicente-Ibarra, N	1
MacíasVillanego, MJ	1
Candela Sánchez, E	1
Carrillo Alemán, L	1
Lozano, T	1
Valdés, M	1
Marín, F	1
Sun, J	1
Yang, GH	1
Liu, JX	1
Liu, XL	1
Ma, YQ	1
Lu, RY	1
Zhang, YY	1
Chen, SB	1
Zhao, JH	1
Ji, WJ	1
Zhou, X	1
Li, YM	1
Dehghani, P	3
Lavoie, A	2
Lavi, S	3
Crawford, JJ	2
Harenberg, S	2
Zimmermann, RH	2
Booker, J	2
Kelly, S	2
Cantor, WJ	2
Mehta, SR	4
Bagai, A	2
Goodman, SG	4
Cheema, AN	3
Tong, MS	1
Sung, PH	1
Liu, CF	1
Chen, KH	1
Chung, SY	1
Chua, S	1
Chen, CJ	1
Lee, WC	1
Chai, HT	1
Yip, HK	1
Chang, HW	1
Giustino, G	1
Mehran, R	4
Dangas, GD	2
Kirtane, AJ	2
Redfors, B	1
Généreux, P	2
Brener, SJ	1
Prats, J	1
Pocock, SJ	3
Deliargyris, EN	1
Stone, GW	3
Rakowski, T	2
Siudak, Z	2
Dziewierz, A	2
Plens, K	1
Kleczyński, P	1
Dudek, D	2
Bossard, M	1
Granger, CB	2
Tanguay, JF	1
Montalescot, G	1
Faxon, DP	1
Jolly, SS	1
Widimsky, P	1
Niemela, K	1
Natarajan, MK	1
Gao, P	1
Fox, KAA	1
Yusuf, S	1
Yang, A	1
Pon, Q	1
Fonseca, FAH	1
Izar, MC	1
Maugeri, IML	1
Berwanger, O	1
Damiani, LP	1
Pinto, IM	1
Szarf, G	1
França, CN	1
Bianco, HT	1
Moreira, FT	1
Caixeta, A	1
Alves, CMR	1
Soriano Lopes, A	1
Klassen, A	1
Tavares, MFM	1
Fonseca, HA	1
Carvalho, ACC	1
Novkovic, M	1
Matic, D	1
Kusic-Tisma, J	1
Antonijevic, N	1
Radojkovic, D	1
Rakicevic, L	1
De Luca, L	1
Pennacchi, M	1
Musumeci, G	1
D'Ascenzo, F	1
Gallo, P	1
Rigattieri, S	1
Granatelli, A	1
Berti, S	1
Gulizia, MM	1
Bolognese, L	1
Lin, TT	1
Lai, HY	1
Chan, KA	1
Yang, YY	1
Lai, CL	1
Lai, MS	1
Nijjer, SS	1
Pavlovic, M	1
Apostolovic, S	1
Stokanovic, D	1
Lilic, J	1
Konstantinovic, SS	1
Zvezdanovic, JB	1
Marinkovic, V	1
Nikolic, VN	1
Yu, HR	1
Wei, YY	1
Ma, JG	1
Geng, XY	1
Furlan, S	1
Borzak, S	1
Lerman, TT	1
Zahger, D	1
Arad, J	1
Gilutz, H	1
Reitblat, O	1
Shimony, A	1
Madhavan, MV	1
Xu, K	1
Witzenbichler, B	2
Yahagi, K	1
Virmani, R	1
Kesavamoorthy, B	1
Mont'Alverne-Filho, JR	1
Rodrigues-Sobrinho, CR	1
Medeiros, F	1
Falcão, FC	1
Falcão, JL	1
Silva, RC	1
Croce, KJ	1
Nicolau, JC	2
Valgimigli, M	1
Serruys, PW	1
Lemos, PA	1
Hromádka, M	1
Bernat, I	1
Seidlerová, J	1
Jirouš, Š	1
Dragounová, E	1
Pechman, V	1
Tůmová, P	1
Rokyta, R	1
Tang, X	1
Li, R	1
Jing, Q	1
Wang, Q	1
Liu, P	1
Zhang, P	1
Sardella, G	1
Calcagno, S	1
Mancone, M	1
Lattuca, B	1
Fabbro-Peray, P	1
Leclercq, F	1
Schmutz, L	1
Ledermann, B	1
Cornillet, L	1
Benezet, JF	1
Macia, JC	1
de La Coussaye, JE	1
Messner-Pellenc, P	1
Cayla, G	1
Li, J	1
Hu, S	1
Yu, Y	1
Yan, XF	1
Jiang, LX	1
Rafique, AM	1
Nayyar, P	1
Wang, TY	1
Baber, U	2
Berger, PB	1
Tobis, J	1
Currier, J	1
Dave, RH	1
Henry, TD	1
Alyasin, N	1
Prech, M	1
Bartela, E	1
Janus, M	1
Jeremicz, I	1
Araszkiewicz, A	1
Urbanska, L	1
Pyda, M	1
Grajek, S	1
Sawina, A	1
Khan, JN	1
Greenwood, JP	1
Nazir, SA	1
Lai, FY	1
Dalby, M	1
Curzen, N	1
Hetherington, S	1
Kelly, DJ	1
Blackman, D	1
Peebles, C	1
Wong, J	1
Flather, M	1
Swanton, H	1
Gershlick, AH	1
McCann, GP	1
Dillinger, JG	1
Saeed, A	1
Spagnoli, V	1
Sollier, CB	1
Sideris, G	1
Silberman, SM	1
Voicu, S	1
Drouet, L	1
Henry, P	1
Di Vito, L	1
Versaci, F	1
Limbruno, U	1
Pawlowski, T	1
Gatto, L	1
Romagnoli, E	1
Cattabiani, MA	1
Micari, A	1
Trivisonno, A	1
Marco, V	1
Prati, F	1
Samoš, M	1
Fedor, M	1
Kovář, F	1
Galajda, P	1
Bolek, T	1
Stančiaková, L	1
Fedorová, J	1
Staško, J	1
Kubisz, P	1
Mokáň, M	1
Yadlapati, A	1
Gajjar, M	1
Schimmel, DR	1
Ricciardi, MJ	1
Flaherty, JD	1
Lee, MJ	1
Baek, YS	1
Shin, SH	1
Woo, SI	1
Kim, DH	1
Kwan, J	1
Park, KS	2
Ichikawa, S	1
Tsukahara, K	1
Minamimoto, Y	1
Kimura, Y	1
Matsuzawa, Y	1
Maejima, N	1
Iwahashi, N	1
Hibi, K	1
Kosuge, M	1
Ebina, T	1
Kimura, K	1
Liang, JJ	1
Fenstad, ER	1
Janish, CD	1
Sinak, LJ	1
Brice, AE	1
Hernandez, GA	1
Sanchez, M	1
Haynick, M	1
Mendoza, CE	1
Déry, JP	1
Fisher, HN	1
Zhang, X	1
Zhu, YE	1
Welsh, RC	1
Cieza, T	1
Henderson, MA	1
Lutchmedial, S	1
Siega, AJ	1
Wong, BY	1
Kokis, A	1
Schoos, MM	1
Yu, J	1
Clemmensen, P	1
Feit, F	1
Gersh, BJ	1
Guagliumi, G	1
Ohman, EM	1
Ciccarelli, G	1
Barbato, E	1
Golino, M	1
Cimmino, G	1
Bartunek, J	1
Di Serafino, L	1
Di Girolamo, D	1
De Bruyne, B	1
Wijns, W	1
Golino, P	1
Kim, WY	1
Rollini, F	1
Franchi, F	1
Angiolillo, DJ	1
Park, Y	1
Tantry, US	1
Koh, JS	1
Ahn, JH	1
Kang, MG	1
Kim, KH	1
Jang, JY	1
Park, JR	1
Hwang, SJ	1
Kwak, CH	1
Hwang, JY	1
Gurbel, PA	1
Jeong, YH	1
Oualim, S	1
Elharda, CA	1
Benzeroual, D	1
Hattaoui, ME	1
Requena, G	1
Maguire, A	1
Blankenberg, S	1
Chen, JY	1
Grieve, R	1
Simon, T	1
Yasuda, S	1
Vega, AM	1
Brieger, D	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within[NCT00623623]	Phase 3	1,899 participants (Actual)	Interventional	2008-03-01	Completed
The Safety and Efficacy of Ticagrelor for Coronary Stenting Post Thrombolysis (SETFAST) Trial.[NCT01930591]	Phase 3	140 participants (Actual)	Interventional	2014-05-31	Completed
Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.[NCT00335452]	Phase 3	25,086 participants (Actual)	Interventional	2006-06-30	Completed
Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)[NCT02428374]	Phase 4	300 participants (Anticipated)	Interventional	2015-05-31	Recruiting
EmploYEd Antithrombotic Therapies in Patients With Acute Coronary Syndromes HOspitalized in iTalian CCUs Registry[NCT02015624]		2,597 participants (Actual)	Observational	2013-12-31	Completed
The China PEACE (Patient-centered Evaluative Assessment of Cardiac Events Retrospective Study of Acute Myocardial Infarction[NCT01624883]		18,000 participants (Actual)	Observational	2012-04-30	Completed
TIGRIS: Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable Coronary Artery dISease in Post Myocardial Infarction Patients[NCT01866904]		9,284 participants (Actual)	Observational	2013-06-19	Terminated (stopped due to Study was terminated in order to secure the data quality of the study in terms of follow-up rates and data completeness.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

Number of Patients With All Cause Death and Shock

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	50
Primary PCI (Group B)	43

This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported (NCT00623623)
Timeframe: 30 days

Number of Patients With All Cause Death and Shock and CHF

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	59
Primary PCI (Group B)	73

This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported. (NCT00623623)
Timeframe: 30 days

Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	100
Primary PCI (Group B)	123

This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

Number of Patients With All Cause Death and Shock and Reinfarction

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	117
Primary PCI (Group B)	135

This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported (NCT00623623)
Timeframe: 30 days

Number of Patients With All Cause Mortality

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	77
Primary PCI (Group B)	85

This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days

Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	43
Primary PCI (Group B)	42

The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS). (NCT00623623)
Timeframe: 30 days

Number of Patients With Cardiac Mortality

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	116
Primary PCI (Group B)	135

This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days

Number of Patients With Cardiogenic Shock

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	31
Primary PCI (Group B)	32

This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported. (NCT00623623)
Timeframe: 30 days

Number of Patients With Congestive Heart Failure (CHF)

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	41
Primary PCI (Group B)	56

This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported. (NCT00623623)
Timeframe: 30 days

Number of Patients With Intracranial Haemorrhage

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	57
Primary PCI (Group B)	72

This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported (NCT00623623)
Timeframe: 30 days

Number of Patients With Ischaemic Stroke

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	9
Primary PCI (Group B)	2

This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

Number of Patients With Major Non-intracranial Bleeds Including Blood Transfusions

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	6
Primary PCI (Group B)	3

This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported (NCT00623623)
Timeframe: 30 days

Number of Patients With Minor Non-intracranial Bleeds

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	61
Primary PCI (Group B)	45

This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days

Number of Patients With Recurrent Myocardial Infarction (Reinfarction)

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	206
Primary PCI (Group B)	191

This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported (NCT00623623)
Timeframe: 30 days

Number of Patients With Rehospitalisation for Cardiac Reasons

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	23
Primary PCI (Group B)	21

This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days

Number of Patients With Rehospitalisation for Non-cardiac Reasons

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	45
Primary PCI (Group B)	41

This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days

Number of Patients With Serious Repeat Target Vessel Revascularization

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	19
Primary PCI (Group B)	11

This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported (NCT00623623)
Timeframe: 30 days

Number of Patients With Serious Resuscitated Ventricular Fibrillation

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	1
Primary PCI (Group B)	2

This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported (NCT00623623)
Timeframe: 30 days

Number of Patients With Serious Resuscitated Ventricular Fibrillation in Association With Invasive Procedures

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	32
Primary PCI (Group B)	38

This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported (NCT00623623)
Timeframe: 30 days

Number of Patients With Total Disabling Stroke

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	10
Primary PCI (Group B)	29

This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

Number of Patients With Total Fatal Stroke

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	2
Primary PCI (Group B)	0

This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

Number of Patients With Total Non-disabling Stroke

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	7
Primary PCI (Group B)	4

This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

Number of Patients With Total Non-intracranial Bleeds

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	8
Primary PCI (Group B)	1

This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days

Number of Patients With Total Stroke (All Types)

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	267
Primary PCI (Group B)	236

This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported (NCT00623623)
Timeframe: 30 days

First Occurrence of CV Death / MI / Stroke - Interaction Clopidogrel Treatment Regimen and ASA Dose Level

First Occurrence of CV Death / MI / Stroke - ASA Dose Comparison

First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	15
Primary PCI (Group B)	5

Intervention	participants (Number)
Clopidogrel 300/75/75 mg + ASA Low Dose	267
Clopidogrel 300/75/75 mg + ASA High Dose	290
Clopidogrel 600/150/75 mg + ASA Low Dose	282
Clopidogrel 600/150/75 mg + ASA High Dose	240

Intervention	participants (Number)
	CV death/MI/Stroke	- CV death	- MI (fatal or not)	- Stroke (fatal or not)
Clopidogrel + ASA High Dose	527	211	251	65
Clopidogrel + ASA Low Dose	546	231	260	55

"The primary endpoint is the first occurrence of any of the following events:~Cardiovascular death (any death with a clear cardiovascular or unknown cause),~Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal)~Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal)~reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC)." (NCT00335452)
Timeframe: 30 days

First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison in PCI Subgroup

Occurrence of Major Bleeding - ASA Dose Level Comparison

Occurrence of Major Bleeding - Clopidogrel Dose Regimen Comparison

Intervention	participants (Number)
	CV death/MI/Stroke	- CV death	- MI (fatal or not)	- Stroke (fatal or not)
Clopidogrel 300/75/75 mg + ASA	557	222	274	61
Clopidogrel 600/150/75 mg + ASA	522	226	237	59

Intervention	participants (Number)
	CV death/MI/Stroke	- CV death	- MI (fatal or not)	- Stroke (fatal or not)
Clopidogrel 300/75/75 mg + ASA	392	132	225	35
Clopidogrel 600/150/75 mg + ASA	330	130	172	28

Intervention	participants (Number)
	Major bleeding	- Severe bleeding	- Major but not severe bleeding
Clopidogrel + ASA High Dose	282	216	73
Clopidogrel + ASA Low Dose	285	215	74

Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC. (NCT00335452)
Timeframe: 30 days

Occurrence of Stent Thrombosis - Clopidogrel Treatment Regimen Comparison

Intervention	participants (Number)
	Major bleeding	- Severe bleeding	- Major but not severe bleeding
Clopidogrel 300/75/75 mg + ASA	255	195	65
Clopidogrel 600/150/75 mg + ASA	313	236	83

This includes definite stent thrombosis (confirmed by angiography or evidence of recent thrombus determined at autopsy or by examination of tissue retrieved following thrombectomy) and probable stent thrombosis (unexplained death having occurred after intracoronary stenting or, MI related to acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any obvious cause) after validation by the EAC. (NCT00335452)
Timeframe: 30 days

Reviews

Trials

Other Studies

38 other studies available for ticlopidine and ST Elevated Myocardial Infarction

Article	Year
Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis. JACC. Cardiovascular interventions, 2016, 05-23, Volume: 9, Issue:10 Topics: Adenosine; Antithrombins; Bayes Theorem; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Cor	2016
Contemporary management of ST-segment elevation myocardial infarction. Internal and emergency medicine, 2016, Volume: 11, Issue:8 Topics: Analgesics; Clopidogrel; Humans; Morphine; Myocardial Infarction; Percutaneous Coronary Intervention	2016

Article	Year
Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study. Kardiologia polska, 2017, Volume: 75, Issue:9 Topics: Adenosine; Aged; Aspirin; Clopidogrel; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy,	2017
Discordance Between VASP Phosphorylation and Platelet Aggregation in Defining High On-Clopidogrel Platelet Reactivity After ST-Segment Elevation Myocardial Infarction. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2018, Volume: 24, Issue:1 Topics: Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Phosphoproteins; Phosphorylat	2018
Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI. American heart journal, 2017, Volume: 192 Topics: Adenosine; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies	2017
Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI. Journal of the American College of Cardiology, 2017, Oct-10, Volume: 70, Issue:15 Topics: Aged; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Cor	2017
Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Journal of the American Heart Association, 2017, Nov-03, Volume: 6, Issue:11 Topics: Acute Coronary Syndrome; Aged; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Female; He	2017
Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI. Journal of thrombosis and thrombolysis, 2018, Volume: 45, Issue:2 Topics: Adenosine; Aged; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Cor	2018
Effects of four antiplatelet/statin combined strategies on immune and inflammatory responses in patients with acute myocardial infarction undergoing pharmacoinvasive strategy: Design and rationale of the B and T Types of Lymphocytes Evaluation in Acute My Trials, 2017, Dec-19, Volume: 18, Issue:1 Topics: Adenosine; Anti-Inflammatory Agents; B-Lymphocytes; Biomarkers; Brazil; Clinical Protocols; Clopidog	2017
Beneficial effects of combined administration of Clopidogrel and Aspirin on the levels of proinflammatory cytokines, cardiac function, and prognosis in ST-segment elevation myocardial infarction: A comparative study. Medicine, 2018, Volume: 97, Issue:45 Topics: Aged; Aspirin; Clopidogrel; Cytokines; Drug Therapy, Combination; Female; Heart; Humans; Male; Middl	2018
Is routine post-procedural anticoagulation warranted after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction? Insights from the HORIZONS-AMI trial. European heart journal. Acute cardiovascular care, 2017, Volume: 6, Issue:7 Topics: Aged; Antithrombins; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combinati	2017
Upstream clopidogrel, prasugrel, or ticagrelor for patients treated with primary angioplasty: Results of an angiographic randomized pilot study. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2016, Volume: 87, Issue:7 Topics: Adenosine; Aged; Angioplasty, Balloon, Coronary; Brazil; Clopidogrel; Coronary Angiography; Drug Adm	2016
Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Journal of cardiovascular pharmacology, 2016, Volume: 68, Issue:2 Topics: Adenosine; Aged; Chi-Square Distribution; China; Clopidogrel; Coronary Thrombosis; Drug Therapy, Com	2016
Infarct Size Following Treatment With Second- Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study. Journal of the American Heart Association, 2016, 05-31, Volume: 5, Issue:6 Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Stenosis; Drug Administration Schedule;	2016
Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction. Journal of cardiovascular medicine (Hagerstown, Md.), 2016, Volume: 17, Issue:9 Topics: Abciximab; Adenosine; Administration, Oral; Aged; Aged, 80 and over; Antibodies, Monoclonal; Clopido	2016
Randomised trial to compare a protective effect of Clopidogrel Versus TIcagrelor on coronary Microvascular injury in ST-segment Elevation myocardial infarction (CV-TIME trial). EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2016, Oct-10, Volume: 12, Issue:8 Topics: Adenosine; Aged; Clopidogrel; Creatine Kinase; Echocardiography; Female; Humans; Male; Microvessels;	2016
Pharmacodynamic Assessment of Platelet Reactivity After a Loading Dose of Prasugrel or Clopidogrel in Patients With ST-Segment Elevation Myocardial Infarction. Circulation journal : official journal of the Japanese Circulation Society, 2016, Nov-25, Volume: 80, Issue:12 Topics: Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Interve	2016
Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. The American journal of cardiology, 2016, Dec-01, Volume: 118, Issue:11 Topics: Aged; Antineoplastic Agents, Phytogenic; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Eur	2016

Article	Year
The impact of high on-treatment platelet reactivity and fibrinogen levels on ischemic events in patients with ST elevation myocardial infarction: a prospective observational study. International journal of clinical pharmacy, 2023, Volume: 45, Issue:2 Topics: Adenosine; Aspirin; Clopidogrel; Fibrinogen; Humans; Percutaneous Coronary Intervention; Platelet Ag	2023
Time-dependent impact of Ticagrelor and Prasugrel on infarct size: Looking beyond antiplatelet effect. International journal of cardiology, 2020, 11-01, Volume: 318 Topics: Clopidogrel; Humans; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Ticagrelor; Ticlop	2020
Ticagrelor versus clopidogrel in real-world patients with ST elevation myocardial infarction: 1-year results by propensity score analysis. BMC cardiovascular disorders, 2017, 04-05, Volume: 17, Issue:1 Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Electrocardiog	2017
Outcome of Triple Antiplatelet Therapy Including Cilostazol in Elderly Patients with ST-Elevation Myocardial Infarction who Underwent Primary Percutaneous Coronary Intervention: Results from the INTERSTELLAR Registry. Drugs & aging, 2017, Volume: 34, Issue:6 Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male;	2017
Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Journal of the American Heart Association, 2016, 06-13, Volume: 5, Issue:6 Topics: Aged; Aspirin; Catheterization, Peripheral; Clopidogrel; Coronary Angiography; Enoxaparin; Female; F	2016
Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Archives of cardiovascular diseases, 2017, Volume: 110, Issue:11 Topics: Aged; Area Under Curve; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Ang	2017
Ischemic stroke complicating thrombolytic therapy with tenecteplase for ST elevation myocardial infarction: two case reports. Journal of medical case reports, 2017, Jun-11, Volume: 11, Issue:1 Topics: Aged; Aspirin; Clopidogrel; Electrocardiography; Fibrinolytic Agents; Heparin; Humans; Ischemic Atta	2017
Non-invasive management of post-partum spontaneous left main coronary artery dissection using cardiac computed tomography angiography. European heart journal. Cardiovascular Imaging, 2017, 10-01, Volume: 18, Issue:10 Topics: Adult; Aspirin; Bisoprolol; Cesarean Section; Clopidogrel; Computed Tomography Angiography; Conserva	2017
Evaluation of On-Clopidogrel platelet reactivity overtime, SYNTAX SCORE, genetic polymorphisms and their relationship to one year clinical outcomes in STEMI patients undergoing PCI. Minerva cardioangiologica, 2018, Volume: 66, Issue:1 Topics: Adult; Aged; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Diabetes Mellitus; Female; Foll	2018
Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes. Journal of cardiovascular pharmacology and therapeutics, 2018, Volume: 23, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Clopidogrel; Female; Hospitalization; Humans;	2018
Impact of Double Loading Regimen of Clopidogrel on Final Angiographic Results, Incidence of Upper Gastrointestinal Bleeding and Clinical Outcomes in Patients with STEMI Undergoing Primary Coronary Intervention. International heart journal, 2017, Oct-21, Volume: 58, Issue:5 Topics: Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gast	2017
Contemporary use of P2Y Journal of thrombosis and thrombolysis, 2018, Volume: 45, Issue:1 Topics: Adenosine; Adult; Aged; Clopidogrel; Humans; Middle Aged; Percutaneous Coronary Intervention; Platel	2018
Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel. European journal of clinical pharmacology, 2018, Volume: 74, Issue:4 Topics: Aged; Chi-Square Distribution; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Predisposition	2018
[Temporal evolution of antithrombotic therapy use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in Italy: comparison between the EYESHOT and SCOPE registries]. Giornale italiano di cardiologia (2006), 2018, Volume: 19, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Fibrinolytic Agents; Humans; Italy; Percutaneous Co	2018
Single and dual antiplatelet therapy in elderly patients of medically managed myocardial infarction. BMC geriatrics, 2018, 04-05, Volume: 18, Issue:1 Topics: Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy, Combination; Electrocardiogra	2018
Clinical outcomes of potent antiplatelets compared with clopidogrel in ST elevation myocardial infarction. Heart (British Cardiac Society), 2018, Volume: 104, Issue:20 Topics: Clopidogrel; Humans; Percutaneous Coronary Intervention; ST Elevation Myocardial Infarction; Ticlopi	2018
The association of clopidogrel and 2-oxo-clopidogrel plasma levels and the 40 months clinical outcome after primary PCI. International journal of clinical pharmacy, 2018, Volume: 40, Issue:6 Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Chest Pain; Clopidogrel; Coronary Artery Di	2018
After PCI with 2nd-generation DESs for STEMI, dual-antiplatelet therapy for 6 mo was noninferior to 12 mo. Annals of internal medicine, 2019, 01-15, Volume: 170, Issue:2 Topics: Drug-Eluting Stents; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST	2019
In-hospital switching from clopidogrel to prasugrel following thrombolysis for ST-elevation myocardial infarction: a 3-year single center experience. European heart journal. Acute cardiovascular care, 2016, Volume: 5, Issue:3 Topics: Aged; Clopidogrel; Female; Hospitalization; Humans; Male; Middle Aged; Percutaneous Coronary Interve	2016
Very late scaffold thrombosis of everolimus-eluting bioresorbable scaffold following implantation in STEMI after discontinuation of dual antiplatelet therapy. Cardiovascular intervention and therapeutics, 2017, Volume: 32, Issue:1 Topics: Absorbable Implants; Adult; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Coronary Vessels	2017
Access-site bleeding and radial artery occlusion in transradial primary percutaneous coronary intervention: influence of adjunctive antiplatelet therapy. Coronary artery disease, 2016, Volume: 27, Issue:4 Topics: Abciximab; Adenosine; Aged; Antibodies, Monoclonal; Catheterization, Peripheral; Clopidogrel; Female	2016
Different Prasugrel Administration in STEMI Patients: Go Faster and No Fear to Crush! Journal of the American College of Cardiology, 2016, 05-03, Volume: 67, Issue:17 Topics: Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonist	2016
One-year incidence and clinical impact of bleeding events in patients treated with prasugrel or clopidogrel after ST-segment elevation myocardial infarction. Archives of cardiovascular diseases, 2016, Volume: 109, Issue:5 Topics: Aged; Clopidogrel; Female; Follow-Up Studies; France; Hemorrhage; Humans; Incidence; Male; Middle Ag	2016
[ST-segment elevation myocardial infarction in the eastern urban China: from 2001 to 2011]. Zhonghua xin xue guan bing za zhi, 2016, Apr-24, Volume: 44, Issue:4 Topics: Aged; Aspirin; China; Clopidogrel; Female; Hospitalization; Hospitals; Humans; Logistic Models; Male	2016
Clopidogrel loading dose in the management of ST elevation myocardial infarction: Still a debate! Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing, 2016, Volume: 34, Issue:2 Topics: Clopidogrel; Guideline Adherence; Humans; Platelet Aggregation Inhibitors; ST Elevation Myocardial I	2016
Effect of a combination of antiplatelet and antithrombotic pretreatment on myocardial perfusion in patients with an acute ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention. Coronary artery disease, 2016, Volume: 27, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Clopidogrel; Coronary Angiography; Coronary Cir	2016
Prehospital Clopidogrel Administration in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary PCI: Real-Life Experience From the Multicenter NRDES Registry. The Journal of invasive cardiology, 2016, Volume: 28, Issue:6 Topics: Aged; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Electrocardiography; Fema	2016
High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction. Thrombosis research, 2016, Volume: 144 Topics: Acute Disease; Adenosine; Aspirin; Blood Platelets; Brain Ischemia; Cardiovascular Diseases; Clopido	2016
The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study. Journal of diabetes research, 2016, Volume: 2016 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Clopidogrel; Diabetes Mellitus, Type	2016
Left ventricular non-compaction cardiomyopathy: Incidental diagnosis after ST-elevation myocardial infarction. Acute cardiac care, 2016, Volume: 18, Issue:1 Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiomyopathy, Hypertrophic, Familial; Clopidogrel;	2016
In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention. Platelets, 2017, Volume: 28, Issue:3 Topics: Adenosine; Blood Platelets; Clopidogrel; Drug Administration Schedule; Drug Dosage Calculations; Dru	2017
Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (C American heart journal, 2016, Volume: 181 Topics: Adenosine; Adult; Aged; Aged, 80 and over; Canada; Clopidogrel; Drug Substitution; Emergency Medical	2016
Prognostic Factors in Patients With Stemi Undergoing Primary PCI in the Clopidogrel Era: Role of Dual Antiplatelet Therapy at Admission and the Smoking Paradox on Long-Term Outcome. Journal of interventional cardiology, 2017, Volume: 30, Issue:1 Topics: Aged; Belgium; Clopidogrel; Female; Hospitalization; Humans; Italy; Male; Middle Aged; Percutaneous	2017
Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study. Journal of the American College of Cardiology, 2017, 01-17, Volume: 69, Issue:2 Topics: Humans; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; ST Elevation Myocardial Infarct	2017
Reply: Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study. Journal of the American College of Cardiology, 2017, 01-17, Volume: 69, Issue:2 Topics: Humans; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; ST Elevation Myocardial Infarct	2017
Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction: The REMODELING Trial. Thrombosis and haemostasis, 2017, 05-03, Volume: 117, Issue:5 Topics: Aged; Aspirin; Biomarkers; Blood Platelets; C-Reactive Protein; Chi-Square Distribution; Clopidogrel	2017
Pulmonary alveolar hemorrhage mimicking a pneumopathy: a rare complication of dual antiplatelet therapy for ST elevation myocardial infarction. The Pan African medical journal, 2016, Volume: 24 Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Lung Diseases; Middle A	2016
Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease (TIGRIS) observational study. International journal of cardiology, 2017, Jun-01, Volume: 236 Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Femal	2017

Intervention	participants (Number)
	Stent trombosis	- Definite	- Probable
Clopidogrel 300/75/75 mg + ASA	200	111	89
Clopidogrel 600/150/75 mg + ASA	135	58	77